Claritas Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLAZF research report →
Companyclaritaspharma.com
Claritas Pharmaceuticals, Inc. , a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs. The company was formerly known as Kalytera Therapeutics, Inc.
- CEO
- Robert Farrell
- IPO
- 2016
- Employees
- 3
- HQ
- San Rafael, CA, US
Price Chart
Valuation
- Market Cap
- $3.66K
- P/E
- 0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -0.33
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -436.27%
- ROIC
- 482.39%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $4.21M · 119.85%
- EPS
- $0.16 · 116.84%
- Op Income
- $-3,276,000
- FCF YoY
- 95.23%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.64
- Avg Volume
- 226.712
Get TickerSpark's AI analysis on CLAZF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CLAZF Coverage
We haven't published any research on CLAZF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CLAZF Report →